title: Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
abstract: BACKGROUND
  Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have demonstrated promising results in the treatment of peritoneal carcinomatosis (PC). The purpose of this study was to assess the impact of this combined procedure on quality of life (QoL).
  
  
  METHODS
  A prospective single centre study of 216 consecutive patients treated with CRS and HIPEC was conducted using the Gastro-Intestinal Quality of Life Index questionnaire (GIQLI), completed preoperatively and at 1, 3, 6 and 12 months.
  
  
  RESULTS
  Questionnaire compliance was 81%, 90%, 89%, 89% and 74% at baseline, 1, 3, 6 and 12 months respectively. QoL was significantly decreased up to 6 months and returned to baseline at 12 months. In multivariate analysis, factors decreasing QoL were origin of PC at 3 months, presence of stoma at 6 months and length of surgery over 270 min and disease recurrence at 12 months.
  
  
  CONCLUSIONS
  Despite morbidity associated with CRS and HIPEC, QoL returned to baseline at one year after surgery. This treatment strategy should be considered for the treatment of peritoneal carcinomatosis.
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France.
authors.forename: G
authors.initials: G
authors.lastname: Passot
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France.
authors.forename: N
authors.initials: N
authors.lastname: Bakrin
authors.affiliation: Hospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France.
authors.forename: A S
authors.initials: AS
authors.lastname: Roux
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France.
authors.forename: D
authors.initials: D
authors.lastname: Vaudoyer
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France.
authors.forename: F-N
authors.initials: FN
authors.lastname: Gilly
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France. Electronic address: olivier.glehen@chu-lyon.fr.
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; Université Lyon 1, EMR 37-38, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Cotte
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D000077146:Irinotecan; D008297:Male; D008654:Mesothelioma / Q000628:therapy; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009378:Neoplasms, Multiple Primary / Q000628:therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D010537:Peritoneum / Q000601:surgery*; D011446:Prospective Studies; D011553:Pseudomyxoma Peritonei / Q000628:therapy*; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D016685:Mitomycin; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin
keywords: Cytoreductive surgery; Peritoneal carcinomatosis; Quality of life